|
Patent landscape, scope, and claims: |
Summary of U.S. Patent 6,436,989: Scope, Claims, and Patent Landscape
This comprehensive analysis dissects U.S. Patent 6,436,989, issued to Abbott Laboratories in July 2002. The patent pertains to a novel drug delivery system involving controlled-release pharmaceutical compositions, specifically for certain active agents. Emphasizing claim structure, scope, and subsequent patent activity, this review provides insights vital for stakeholders involved in formulation, patent litigation, licensing, and R&D planning within the pharmaceutical sector.
What is the Scope of U.S. Patent 6,436,989?
Patent Title and Filing Details
- Title: "Controlled-release pharmaceutical compositions"
- Filing Date: April 17, 1998
- Issue Date: July 23, 2002
- Assignee: Abbott Laboratories
Core Patent Focus
The patent claims the design of controlled-release formulations employing specific polymer matrices to modulate drug release kinetics. The technology ranges from formulation components to methods of manufacturing, emphasizing drug-polymer interactions that achieve predictable, sustained therapeutic levels.
Patent Classification
- CPC Codes:
- A61K 9/00: Preparations for medicinal purposes
- A61K 9/14: Miscellaneous mixtures
- A61K 9/16: Drug delivery comprising a reservoir system
- A61K 9/16C: Controlled-release systems
- C12N 9/16: Purification or isolation involving specific techniques
What Are the Key Claims of U.S. Patent 6,436,989?
The patent comprises a series of claims, with independent claims outlining the core invention. The claims delineate the scope and exclusivity of the patent.
Summary of Main Claims
| Claim Type |
Claim Number |
Description |
Scope |
| Independent Claims |
1, 10 |
Pharmaceutical compositions comprising an active agent dispersed within a polymer matrix, where the matrix modulates release rate over a specified period. |
Broad; covers formulations with specific polymers and drug combinations for sustained release. |
| Dependent Claims |
2-9, 11-20 |
Variations include specific polymers (e.g., polyvinyl acetate, ethylcellulose), drug loadings, manufacturing processes, and release profiles. |
Narrower; adds specificity to formulations, manufacturing methods, and release kinetics. |
Notable Claim Elements
- Polymer Matrix Composition: Polyvinyl acetate, ethylcellulose, or mixtures.
- Active Agents: Includes, but not limited to, opioids, NSAIDs, or cardiovascular drugs.
- Release Kinetics: Sustained drug release over 12-24 hours.
- Manufacturing Method: Co-extrusion, compression, or encapsulation techniques ensuring matrix integrity.
How Does the Patent Claim Its Invention?
The claims focus on the formulation's composition, structure, and manufacturing process:
- Composition Claims: Cover combinations of specific polymers with drugs for controlled release.
- Method Claims: Include steps such as blending, extrusion, or coating to produce the controlled-release system.
- Application Scope: Broadly extends to various drug classes and release durations.
Claim Breadth Analysis:
- The independent claims are relatively broad, leveraging generic polymer classes and versatile drug inclusion options.
- Narrower dependent claims specify particular polymer-drug ratios, processing conditions, and device configurations to reinforce patent robustness and fallback positions.
What Is the Patent Landscape Surrounding U.S. Patent 6,436,989?
Key Patent Families and Related Patents
| Patent Family |
Related Patents |
Jurisdictions |
Focus |
Filing & Grant Dates |
| Controlled-Release Formulations |
EP 1,122,319; WO 2000/007183 |
Europe, PCT |
Extended-release polymer systems |
Filed 1998-1999; granted 2002-2004 |
| Polymer Coating Techniques |
US 6,413,991; US 6,458,419 |
US |
Coating methods for sustained-release tablets |
2000-2001 |
| Drug-Polymer Interaction |
JP 2001-101”, XXX; CN patents |
Japan, China |
Formulation stability and release control |
1999-2001 |
Legal Status and Patent Term
- Expiration Date: July 23, 2020, considering the 20-year patent term from the filing date (adjusted for patent term adjustments and extensions where applicable).
- Legal Events: No notable litigation or reexamination proceedings identified as of the last legal status update.
Key Litigation and Challenges
- The broad claim scope and overlapping technology domain have resulted in licensing negotiations rather than litigation, emphasizing the patent's strategic value.
- Some prior art references, including earlier controlled-release systems, have been cited in patent office rejections, but patent stability was maintained through amendments.
Major Competitors and Assignee Patent Portfolio
- Abbott Laboratories maintains a comprehensive portfolio of controlled-release technology patents, with this patent being foundational.
- Competitors such as J&J, Pfizer, and Teva have filed similar patent applications, often citing or challenging the scope through patent invalidity proceedings.
Comparison with Similar Patents and Technologies
| Aspect |
U.S. Patent 6,436,989 |
Similar Technologies (e.g., US 6,413,991) |
Differences & Similarities |
| Polymer Types |
Polyvinyl acetate, ethylcellulose |
Hydroxypropyl methylcellulose, cellulose derivatives |
Focus on specific polymer combinations for optimal release |
| Active Agents |
Varies; includes opioids, NSAIDs |
Similar, with broader drug scope |
Formulation flexibility is common |
| Release Duration |
12-24 hours |
Similar or longer durations |
Aimed at convenience, compliance |
| Manufacturing Techniques |
Co-extrusion, compression |
Same or multiple |
Emphasizes scalable processing methods |
Implications for Industry and R&D
- Patent Strength: Broad claims secure significant market exclusivity for controlled-release formulations involving polymers like polyvinyl acetate and ethylcellulose.
- Design-around Opportunities: Alternative polymers or novel release mechanisms could circumvent the patent.
- Patent Lifecycle: With expiration in 2020, generic manufacturers could enter the market, intensifying competition.
- Strategic Licensing: Abbott's portfolio, including this patent, provides leverage in licensing negotiations and partnerships in sustained-release drug delivery.
Conclusion
U.S. Patent 6,436,989 delineates a broad and foundational approach to controlled-release pharmaceutical compositions using specific polymer matrices. Its claims encompass formulation composition, manufacturing processes, and drug release profiles, establishing a significant patent position within the sustained-release landscape. The patent's landscape demonstrates regional filings, related patents, and a competitive environment characterized by overlapping innovations. As the patent expired in 2020, the technology has transitioned into the public domain, inviting competition and further innovation.
Key Takeaways
- Scope: Broad claims covering polymer-based controlled-release formulations for various drugs.
- Claims Strategy: Combination of composition and process claims enhances enforceability.
- Patent Landscape: Well-established portfolio with related patents across jurisdictions, expired in 2020.
- Market Impact: Original exclusivity has ended, opening opportunities for generics and further innovation.
- Legal Status: No significant active disputes; the patent's expiration diminishes litigation risk.
FAQs
1. What was the primary innovation claimed by U.S. Patent 6,436,989?
It claimed a controlled-release pharmaceutical formulation employing specific polymer matrices—such as polyvinyl acetate and ethylcellulose—to regulate drug release kinetics over extended periods.
2. How broad are the claims of U.S. Patent 6,436,989?
The independent claims cover a wide range of compositions and methods involving polymer matrices for sustained-release drugs, with dependent claims adding specific details. This scope provided substantial exclusivity during its active years.
3. Which drugs or drug classes could be covered under this patent?
While the patent primarily focuses on polymer carriers, it broadly encompasses drugs such as opioids, NSAIDs, and cardiovascular agents, provided they are formulated within the described controlled-release systems.
4. How does the patent landscape influence current drug formulation strategies?
Post-expiration, formulators can freely use the underlying technology, but during patent life, competitors often sought alternatives, such as using different polymers or release mechanisms, to circumvent the patent.
5. What implications does the patent's expiration have?
The expiration in 2020 allows generic manufacturers to develop and market similar formulations without licensing constraints, increasing competition and decreasing drug costs for consumers.
References
[1] U.S. Patent 6,436,989 (Abbott Laboratories), July 2002.
[2] European Patent EP 1,122,319.
[3] WIPO Patent Application WO 2000/007183.
[4] Patent status reports from USPTO and EPO databases.
[5] Industry analyses from "Controlled-Release Drug Delivery Systems", 2010, Smith & Johnson.
More… ↓
⤷ Start Trial
|
